References
Mychalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 2008;8:339–447.
Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895–900.
Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317–2323.
Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–257.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ahn, S.J., Oh, J.Y., Kim, M.K. et al. Treating refractory scleritis with infliximab. Jpn J Ophthalmol 53, 286–287 (2009). https://doi.org/10.1007/s10384-008-0652-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-008-0652-5